Indium (111in) Dtpa Curium Netherlands B.V. (Pentetic Acid, Indium (111in) Pentetate)

The drug combines the gamma‑emitting isotope indium‑111 with the chelating agent pentetate (DTPA). After intrathecal injection, the complex stays within the cerebrospinal fluid and emits gamma photons that are captured by scintigraphic cameras, producing detailed images of CSF flow and potential leak sites.

The administered activity is determined by the prescribing physician or nuclear medicine specialist based on the specific diagnostic protocol, patient size, and imaging equipment. Dosing is individualized and documented in the patient’s medical record; no standard dose is provided in public literature.

Use during pregnancy is generally avoided unless the diagnostic benefit clearly outweighs potential fetal risk, as radiation exposure may affect the developing fetus. For breastfeeding mothers, the drug may be secreted in milk; discontinuation of nursing or a sufficient waiting period after administration is recommended.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

The most common alternative is Technetium‑99m DTPA, which also images CSF but has a shorter half‑life and different photon energy. Indium‑111 provides longer imaging windows and higher resolution for delayed studies, while Technetium‑99m offers faster imaging but may be less suitable for prolonged assessments.

The product must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original sealed container. It should not be frozen or shaken, and handling must follow radiation safety protocols, including use of shielding and personal protective equipment.

Administration is performed by a qualified healthcare professional via a sterile intrathecal injection, typically into the lumbar subarachnoid space. The procedure follows aseptic technique, and the patient is monitored for immediate adverse reactions before proceeding with imaging.

Serious risks include severe allergic reactions such as anaphylaxis, significant headache indicating increased intracranial pressure, and rare radiation‑induced bone‑marrow suppression. Prompt recognition and appropriate medical intervention are essential if any of these events occur.

Patients with known hypersensitivity to indium‑111, pentetate, or any component of the formulation should avoid the drug. It is also contraindicated in individuals where intrathecal injection is unsafe, such as those with active infection at the injection site, uncontrolled coagulopathy, or severe spinal abnormalities.